Rational Therapeutic Combinations with Histone Deacetylase Inhibitors for the Treatment of Cancer-Reference-Cited by-同舟云学术

Rational Therapeutic Combinations with Histone Deacetylase Inhibitors for the Treatment of Cancer

Published:2011-02-23 Issue:2 Volume:7 Page:263-283
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncol.

Author:

Thurn K Ted¹,Thomas Scott¹,Moore Amy¹,Munster Pamela N¹

Affiliation:

1. Department of Medicine, Hematology/Oncology Division. University of California, San Francisco, CA, USA; 1600 Divisadero St, Room A722, Box 1770, San Francisco, CA94115, USA.

Funder

National Institutes of Health

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.2217/fon.11.2

Reference177 articles.

1. Histone Deacetylase Inhibitors

2. Functional Domains of Histone Deacetylase-3

3. Isolation and Characterization of cDNAs Corresponding to an Additional Member of the Human Histone Deacetylase Gene Family

4. Sirtuins inhibitors: The approach to affinity and selectivity

5. Histone deacetylase inhibitors in cancer treatment

Cited by 225 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis, and biological evaluation of novel PI3Kδ/HDAC6 dual inhibitors for the treatment of non-Hodgkin's lymphoma;European Journal of Medicinal Chemistry;2025-10

2. Impact of HDAC6-mediated progesterone receptor expression on the response of breast cancer cells to hormonal therapy;European Journal of Pharmacology;2024-11

3. Slow-Binding and Covalent HDAC Inhibition: A New Paradigm?;JACS Au;2024-10-31

4. Histone deacetylase inhibitors for leukemia treatment: current status and future directions;European Journal of Medical Research;2024-10-26

5. Targeted small molecule therapy and inhibitors for lymphoma;Future Medicinal Chemistry;2024-07-17